New York-based ZIOPHARM Oncology, Inc is a biopharmaceutical firm that specialises in acquiring, developing and commercialising cancer drugs in North America. The firm has a number of clinical programmes in progress, including developing and manufacturing Palifosfamide for use in a range of cancer treatments, Darinaparsin, an anti-mitochondrial compound for the treatment of acute promyelocytic leukemia, as well as Indibulin, a novel small molecular-weight inhibitor of tubulin polymerization. The company is also focussing on biotherapeutics that make use of DNA.